Related Experiment Video
Updated: Mar 8, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.9K
Long noncoding RNA CCAT2 can predict metastasis and poor prognosis: A meta-analysis
Yang-Hua Fan1, Hua Fang1, Chen-Xing Ji1
1Department of Neurosurgery, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 17, 2017
Summary
High Colon cancer-associated transcript 2 (CCAT2) expression is linked to poorer outcomes in cancer patients. This suggests CCAT2 may be a useful biomarker for predicting cancer prognosis and metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colon cancer-associated transcript 2 (CCAT2) is a known dysregulated transcript in various cancers.
- Understanding the prognostic role of CCAT2 is crucial for cancer patient management.
Purpose of the Study:
- To conduct a meta-analysis to clarify the function of CCAT2 as a prognostic marker in malignant tumors.
- To evaluate the association between CCAT2 expression and patient survival and clinicopathological features.
Main Methods:
- Systematic literature search of electronic databases (PubMed, Medline, OVID, Cochrane Library, Web of Science) up to October 20, 2016.
- Meta-analysis of Hazard Ratios (HR) for survival outcomes and Odds Ratios (OR) for clinicopathological parameters.
- Statistical analysis performed using RevMan5.3 software.
Main Results:
- Six studies with 725 cancer patients were included.
- High CCAT2 expression significantly correlated with poorer overall survival (OS) (HR=2.30) and progression-free survival (PFS) (HR=2.76).
- CCAT2 expression was significantly associated with lymph node metastasis (LNM) (OR=4.33), distant metastasis (DM) (OR=11.66), and tumor stage (OR=2.58).
Conclusions:
- High CCAT2 expression is a significant predictor of poor OS, PFS, LNM, DM, and advanced tumor stage.
- CCAT2 emerges as a potential novel biomarker for predicting poor prognosis and metastasis in various cancers.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
02:39lncRNA - Long Non-coding RNAs
3.8K
3.8K
02:30Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K